Of note, a similar proportion of patients in the empagliflozin and placebo groups (43% and 40%, respectively) were using an ...

GLP-1 receptor agonist or SGLT2 inhibitor prescribing became more common for people with type 1 diabetes in recent years, a ...

Sodium-glucose cotransporter 2 (SGLT2) inhibitors may protect the kidneys better than glucagon-like peptide 1 receptor ...

On Halloween, Lexicon was haunted again as an FDA advisory committee voted 11-3 to reject Zynquista as an accompanying ...

Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) are a relatively new group of medications originally developed ...

On Thursday, members of the Endocrinologic and Metabolic Drugs Advisory Committee will help the FDA decide whether the ...

Greatest increase in SGLT2 inhibitor use seen in subgroups with cardiovascular disease; greatest increase in GLP-1 RA for those with obesity.

Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with ...

A recent case report highlights the importance of understanding the possibility of the development of Euglycemic diabetic ...

A collaboration of researchers led by Emory University Rollins School of Public Health, Atlanta, is urging caution when ...

Renal glucose reabsorption involves two transporter families: the SGLTs secondary active Na + /D-glucose co-transporters located at the brush border of tubular cells (SGLT2 and SGLT1) and the ...